Jara Bouma
PhD candidate
- Name
- Dr. J. Bouma
- Telephone
- +31 71 527 2727
- j.bouma@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0002-6572-6158
In 2014, I started with the Bachelor’s program of Life Science and Technology at the University of Groningen with a specialization in medical pharmaceutical sciences and an exchange program at the University of Umeå (Sweden). During my internship at the Department of Clinical Pharmacy and Pharmacology (University Medical Center Groningen), I investigated the molecular mechanism of several compounds on the α1-adrenergic receptor which triggered my interest in molecular pharmacology research. Therefore, I continued with the Bio-Pharmaceutical Sciences Master at Leiden University. For my first internship at the Division of Drug Discovery and Safety, I investigated structure-affinity and structure-kinetic relationships of the hENT1. Thereafter, I performed my second internship at the Leiden University Medical Center where I histologically analyzed and compared stem cell-derived xenografts and human germ cell tumors. Simultaneously, I took part in the Leiden Leadership Programme during which I also carried out a project at Zorg & Zekerheid. In 2019, I started my PhD at the Division of Drug Discovery and Safety under supervision of prof. dr. L.H. Heitman and prof. dr. M. van der Stelt. I will focus on gaining new insights into targeting the cannabinoid receptor 2 (CB2) from a molecular pharmacological approach.
PhD candidate
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Medicinal Chemistry
- Vlachodimou A., Bouma J., Cleyn M. de, Berthelot D., Pype S., Bosmans J.P., Vlijmen H. van, Wroblowski B., Heitman L.H. & IJzerman A.P. (2024), Kinetic profiling of novel spirobenzo-oxazinepiperidinone derivatives as equilibrative nucleoside transporter 1 inhibitors, Purinergic Signalling 20: 193-205.
- Bouma J. (11 September 2024), It's about time (Dissertatie. Leiden Academic Centre for Drug Research (LADCR), Faculty of Science, Leiden University). Supervisor(s): Heitman L.H. & Stelt M. van de.
- Bouma, J., Broekhuis J.D., Horst C. van der, Kumar P., Ligresti A., Stelt M. van der & Heitman L.H. (2023), Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB2 receptor, Biochemical Pharmacology 218: 115924.
- Li X., Chang H., Bouma J., Paus L.V. de, Mukhopadhyay P., Paloczi J., Mustafa M., Horst C. van der, Kumar S.S., Wu L., Yu Y., Berg R.J.B.H.N. van den, Janssen A.P.A., Lichtman A., Liu Z.J., Pacher P., Stelt M. van der, Heitman L.H. & Hua T. (2023), Structural basis of selective cannabinoid CB2 receptor activation, Nature Communications 14(1): 1447.
- Bouma J., Soethoudt M., Gils N. van, Xia L., Stelt M van der & Heitman L.H. (2022), Cellular assay to study β-arrestin recruitment by the cannabinoid receptors 1 and 2. In: Maccarrone M. (Ed.) Endocannabinoid Signaling. Methods in Molecular Biology no. 2576 New York, U.S.A.: Humana. 189-199.